Switch theme
Sign up to access all valuation multiples
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested for the prevention of complications that arise from cytokine release syndrome, or hyperinflammatory conditions.
2006
25
LTM Revenue $3.1M
LTM EBITDA -$15.1M
$341M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Faron Pharmaceuticals has a last 12-month revenue of $3.1M and a last 12-month EBITDA of -$15.1M.
In the most recent fiscal year, Faron Pharmaceuticals achieved revenue of n/a and an EBITDA of -$27.9M.
Faron Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Faron Pharmaceuticals valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$36.6M | -$27.9M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$37.0M | -$39.8M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | $7.7M | $7.8M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Faron Pharmaceuticals's stock price is GBP 2 (or $3).
Faron Pharmaceuticals has current market cap of GBP 262M (or $338M), and EV of GBP 265M (or $341M).
See Faron Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $341M | $338M | XXX | XXX | XXX | XXX | $-0.28 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Faron Pharmaceuticals has market cap of $338M and EV of $341M.
Faron Pharmaceuticals's trades at 90.4x LTM EV/Revenue multiple, and -18.9x LTM EBITDA.
Analysts estimate Faron Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Faron Pharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $341M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -12.2x | XXX | XXX | XXX |
| P/E | -10.1x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -11.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpFaron Pharmaceuticals's NTM/LTM revenue growth is 148%
Faron Pharmaceuticals's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.0M for the same period.
Over next 12 months, Faron Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Faron Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Faron Pharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | -24% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.0M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Faron Pharmaceuticals acquired XXX companies to date.
Last acquisition by Faron Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Faron Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Faron Pharmaceuticals founded? | Faron Pharmaceuticals was founded in 2006. |
| Where is Faron Pharmaceuticals headquartered? | Faron Pharmaceuticals is headquartered in United Kingdom of Great Britain and Northern Ireland. |
| How many employees does Faron Pharmaceuticals have? | As of today, Faron Pharmaceuticals has 25 employees. |
| Is Faron Pharmaceuticals publicy listed? | Yes, Faron Pharmaceuticals is a public company listed on LON. |
| What is the stock symbol of Faron Pharmaceuticals? | Faron Pharmaceuticals trades under FARN ticker. |
| When did Faron Pharmaceuticals go public? | Faron Pharmaceuticals went public in 2015. |
| Who are competitors of Faron Pharmaceuticals? | Similar companies to Faron Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Faron Pharmaceuticals? | Faron Pharmaceuticals's current market cap is $338M |
| What is the current revenue of Faron Pharmaceuticals? | Faron Pharmaceuticals's last 12-month revenue is $3.1M. |
| What is the current EBITDA of Faron Pharmaceuticals? | Faron Pharmaceuticals's last 12-month EBITDA is -$15.1M. |
| What is the current EV/Revenue multiple of Faron Pharmaceuticals? | Current revenue multiple of Faron Pharmaceuticals is 90.4x. |
| What is the current EV/EBITDA multiple of Faron Pharmaceuticals? | Current EBITDA multiple of Faron Pharmaceuticals is -18.9x. |
| Is Faron Pharmaceuticals profitable? | Yes, Faron Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
